tiprankstipranks
Trending News
More News >
Ars Pharmaceuticals, Inc. (SPRY)
NASDAQ:SPRY
US Market

ARS Pharmaceuticals (SPRY) Income Statement

Compare
564 Followers

ARS Pharmaceuticals Income Statement

Last quarter (Q4 2025), ARS Pharmaceuticals's total revenue was $28.09M, a decrease of -67.56% from the same quarter last year. In Q4, ARS Pharmaceuticals's net income was $-41.32M. See ARS Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 25Dec 24Dec 23Dec 22Mar 22
Total Revenue
$ 84.28M$ 89.15M$ 30.00K$ 1.32M$ 5.51M
Gross Profit
$ 63.85M$ 68.59M$ 30.00K$ 1.32M$ 5.29M
Operating Expenses
$ 243.30M$ 71.67M$ 67.55M$ 36.83M$ 24.75M
Depreciation and Amortization
$ 1.37M$ 79.00K$ 73.00K$ 319.00K$ 213.00K
EBITDA
$ -178.08M$ -3.00M$ -67.45M$ -35.20M$ -19.24M
Operating Income
$ -179.45M$ -3.08M$ -67.52M$ -35.52M$ -19.45M
Other Income/Expenses
$ 8.07M$ 11.37M$ 13.15M$ 834.00K$ -789.00K
Pretax Income
$ -171.38M$ 8.29M$ -54.37M$ -34.68M$ -20.24M
Net Income
$ -171.30M$ 8.00M$ -54.37M$ -34.68M$ -20.24M
Per Share Metrics
Basic EPS
$ -1.74$ 0.08$ -0.57$ -0.87$ -0.70
Diluted EPS
$ -1.74$ 0.08$ -0.57$ -0.87$ -0.70
Weighted Average Shares Outstanding
98.57M 96.94M 95.22M 39.96M 28.87M
Weighted Average Shares Outstanding (Diluted)
98.57M 102.39M 95.22M 39.96M 28.87M
Currency in USD

ARS Pharmaceuticals Earnings and Revenue History